|
US11932633B2
(en)
|
2018-05-07 |
2024-03-19 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
WO2020055761A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
CN113164418A
(zh)
|
2018-12-05 |
2021-07-23 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
WO2021041671A1
(en)
|
2019-08-29 |
2021-03-04 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
TWI829003B
(zh)
*
|
2020-08-12 |
2024-01-11 |
美商建南德克公司 |
喹唑啉化合物之合成
|
|
WO2022056307A1
(en)
|
2020-09-11 |
2022-03-17 |
Mirati Therapeutics, Inc. |
Crystalline forms of a kras g12c inhibitor
|
|
US20230365563A1
(en)
*
|
2020-09-30 |
2023-11-16 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Quinazoline compound and application thereof
|
|
US20240059710A1
(en)
*
|
2020-11-20 |
2024-02-22 |
Jacobio Pharmaceuticals Co., Ltd. |
KRAS G12D Inhibitors
|
|
WO2022132200A1
(en)
|
2020-12-15 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-kras inhibitors
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
BR112023015976A2
(pt)
*
|
2021-02-09 |
2023-12-12 |
Medshine Discovery Inc |
Compostos de anel aromático de pirimidina
|
|
AU2022224511A1
(en)
*
|
2021-02-16 |
2023-08-10 |
Lawrence Livermore National Security, Llc |
Compositions and methods for inhibition of ras
|
|
IL305568A
(en)
*
|
2021-03-12 |
2023-10-01 |
Bristol Myers Squibb Co |
KRAS G12D inhibitors
|
|
CN115260214A
(zh)
*
|
2021-04-29 |
2022-11-01 |
药雅科技(上海)有限公司 |
稠环类krasg12d突变蛋白抑制剂的制备及其应用
|
|
CN115160309B
(zh)
*
|
2021-04-07 |
2024-04-09 |
药雅科技(上海)有限公司 |
Krasg12c突变蛋白杂环类抑制剂的制备及其应用
|
|
CN115141215B
(zh)
*
|
2021-03-30 |
2023-09-15 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
WO2022214102A1
(zh)
*
|
2021-04-09 |
2022-10-13 |
杭州英创医药科技有限公司 |
作为kras g12d抑制剂的杂环化合物
|
|
WO2022221386A1
(en)
*
|
2021-04-14 |
2022-10-20 |
Erasca, Inc. |
Selective kras inhibitors
|
|
WO2022221739A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12d mutant
|
|
JP2024517693A
(ja)
*
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
２－アミノベンゾチアゾール化合物及びその使用方法
|
|
JP2024517695A
(ja)
*
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
CN117222650A
(zh)
*
|
2021-04-30 |
2023-12-12 |
劲方医药科技(上海)有限公司 |
吡啶或嘧啶并环类化合物，其制法与医药上的用途
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
CN115385938A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
苯并嘧啶类化合物、其制备方法及其在医药上的应用
|
|
CN117500799A
(zh)
*
|
2021-06-09 |
2024-02-02 |
伊莱利利公司 |
作为kras g12d抑制剂的取代的稠合吖嗪
|
|
JP2024520791A
(ja)
*
|
2021-06-10 |
2024-05-24 |
レデックス・ファーマ・パブリック・リミテッド・カンパニー |
化合物
|
|
WO2022262686A1
(en)
*
|
2021-06-13 |
2022-12-22 |
Jingrui Biopharma Co., Ltd. |
Kras g12d inhibitors
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2023278600A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Dana-Farber Cancer Institute, Inc. |
Small molecule inhibitors of kras g12d mutant
|
|
EP4373822A2
(en)
|
2021-07-23 |
2024-05-29 |
Theras Inc. |
Compositions and methods for inhibition of ras
|
|
CN117677398A
(zh)
|
2021-07-27 |
2024-03-08 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
|
US20240409558A1
(en)
*
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
EP4417606A4
(en)
*
|
2021-10-15 |
2025-10-22 |
Sunshine Lake Pharma Co Ltd |
NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
WO2023103523A1
(zh)
*
|
2021-12-09 |
2023-06-15 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
MX2024008849A
(es)
*
|
2022-01-21 |
2024-07-25 |
Usynova Pharmaceuticals Ltd |
Compuestos de benzopirimidina y uso de estos.
|
|
IL314486A
(en)
*
|
2022-02-03 |
2024-09-01 |
Mirati Therapeutics Inc |
Quinazoline compounds inhibit PAN-KRAS
|
|
AU2023218370B2
(en)
|
2022-02-09 |
2024-11-28 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2023151621A1
(zh)
*
|
2022-02-11 |
2023-08-17 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
EP4479398A1
(en)
*
|
2022-02-16 |
2024-12-25 |
Amgen Inc. |
Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN114573438A
(zh)
*
|
2022-03-31 |
2022-06-03 |
上海应用技术大学 |
一种单氟氯/溴代丙酮类化合物及其制备方法
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
CN119585287A
(zh)
|
2022-05-06 |
2025-03-07 |
Paq医疗公司 |
Kras g12d蛋白水解靶向嵌合体
|
|
IL317601A
(en)
|
2022-05-25 |
2025-02-01 |
Quanta Therapeutics Inc |
Pyrimidine-based modulators and their uses
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202400600A
(zh)
*
|
2022-06-16 |
2024-01-01 |
美商昂勝醫療科技股份有限公司 |
喹唑啉衍生物、其組成物及方法
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
TW202409002A
(zh)
|
2022-07-21 |
2024-03-01 |
日商安斯泰來製藥股份有限公司 |
作用於g12d突變kras蛋白之雜環化合物
|
|
JP2025525938A
(ja)
*
|
2022-08-05 |
2025-08-07 |
セラス， インコーポレイテッド |
Ｋｒａｓの阻害のための組成物及び方法
|
|
WO2024030647A1
(en)
*
|
2022-08-05 |
2024-02-08 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
TW202412790A
(zh)
|
2022-08-09 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於抑制及/或誘導分解kras蛋白之雜環化合物
|
|
EP4568952A1
(en)
|
2022-08-11 |
2025-06-18 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
JP7733274B1
(ja)
|
2022-08-12 |
2025-09-02 |
アステラス製薬株式会社 |
Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
|
|
AR130192A1
(es)
*
|
2022-08-12 |
2024-11-13 |
Astellas Pharma Inc |
Combinaciones antineoplásicas que comprenden quimioterapia
|
|
CN119855815A
(zh)
*
|
2022-09-21 |
2025-04-18 |
甘李药业股份有限公司 |
一种kras突变蛋白抑制剂、及其制备方法和应用
|
|
AU2023349002A1
(en)
*
|
2022-09-30 |
2025-05-15 |
Trasveda Ltd. |
Compounds with anti-kras mutant tumor activity
|
|
CN117886833A
(zh)
*
|
2022-10-13 |
2024-04-16 |
广东东阳光药业股份有限公司 |
一种嘧啶并吡啶化合物、其药物组合物及其用途
|
|
CN117263959A
(zh)
*
|
2022-10-24 |
2023-12-22 |
药雅科技(上海)有限公司 |
芳香类kras突变蛋白抑制剂的制备及其应用
|
|
JP2026504244A
(ja)
|
2022-11-09 |
2026-02-04 |
レヴォリューション・メディスンズ，インコーポレイテッド |
化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法
|
|
CN116554208A
(zh)
*
|
2022-12-02 |
2023-08-08 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2024158242A1
(ko)
*
|
2023-01-25 |
2024-08-02 |
주식회사 엔바이오스 |
Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
WO2025002302A1
(zh)
*
|
2023-06-28 |
2025-01-02 |
广东东阳光药业股份有限公司 |
嘧啶并吡啶化合物、其药物组合物及其用途
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
WO2025051242A1
(zh)
*
|
2023-09-08 |
2025-03-13 |
泰励生物科技（上海）有限公司 |
Ras抑制剂
|
|
US12599672B2
(en)
|
2023-10-03 |
2026-04-14 |
PAQ Therapeutics Inc. |
KRAS proteolysis targeting chimeras
|
|
TW202523324A
(zh)
*
|
2023-10-08 |
2025-06-16 |
大陸商成都海博為藥業有限公司 |
一種稠環化合物及應用
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
AU2024357850A1
(en)
|
2023-10-09 |
2026-04-23 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
WO2025077770A1
(zh)
*
|
2023-10-10 |
2025-04-17 |
成都海博为药业有限公司 |
一种稠环化合物及在kras抑制剂方面的应用
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025085580A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|